Protagenic Therapeutics, Inc.\new (PTIX) Net income 2018–2026
Protagenic Therapeutics, Inc.\new (PTIX) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
$1.4MFY2026 · since FY2018: -$2.3M → $1.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $1.4M | +138.1% |
| FY2025 | -$3.6M | +28.2% |
| FY2024 | -$5.0M | -40.6% |
| FY2023 | -$3.6M | +21.4% |
| FY2022 | -$4.5M | -77.5% |
| FY2021 | -$2.5M | -45.6% |
| FY2020 | -$1.8M | +31.5% |
| FY2019 | -$2.6M | -13.2% |
| FY2018 | -$2.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PTIX financial trends
PTIX RevenuePTIX Net marginPTIX Gross profitPTIX Gross marginPTIX Operating incomePTIX Operating marginPTIX Operating cash flowPTIX Free cash flowPTIX Capital expendituresPTIX Return on equityPTIX Stock buybacksPTIX Dividends paidPTIX Total assetsPTIX Total liabilitiesPTIX Shareholders’ equityPTIX overview →